Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice

Abstract : Glycogen storage disease type 1a (GSD1a) is a rare disease due to the deficiency in the glucose-6-phosphatase catalytic subunit (encoded by G6pc), which is essential for endogenous glucose production. Despite strict diet control to maintain blood glucose, patients with GSD1a develop hepatomegaly, steatosis and then hepatocellular adenomas (HCA), which can undergo malignant transformation. Recently, gene therapy has attracted attention as a potential treatment for GSD1a. In order to maintain long-term transgene expression, we developed an HIV-based vector, which allowed us to specifically express the human G6PC cDNA in the liver. We analysed the efficiency of this lentiviral vector in the prevention of the development of the hepatic disease in an original GSD1a mouse model, which exhibits G6Pase deficiency exclusively in the liver (L-G6pc-/- mice). Recombinant lentivirus were injected in B6.G6pcex3lox/ex3lox.SAcreERT2/w neonates and G6pc deletion was induced by tamoxifen treatment at weaning. Magnetic resonance imaging was then performed to follow up the development of hepatic tumours. Lentiviral gene therapy restored glucose-6 phosphatase activity sufficient to correct fasting hypoglycaemia during 9 months. Moreover, lentivirus-treated L-G6pc-/- mice presented normal hepatic triglyceride levels, whereas untreated mice developed steatosis. Glycogen stores were also decreased although liver weight remained high. Interestingly, lentivirus-treated L-G6pc-/- mice were protected against the development of hepatic tumours after 9 months of gene therapy while most of untreated LG6pc-/- mice developed millimetric HCA. Thus the treatment of new-borns by recombinant lentivirus appears as an attractive approach to protect the liver from the development of steatosis and hepatic tumours associated to GSD1a pathology.
Type de document :
Article dans une revue
Human Molecular Genetics, Oxford University Press (OUP), 2015, 24 (8), pp.2287-2296. <10.1093/hmg/ddu746>
Liste complète des métadonnées


http://www.hal.inserm.fr/inserm-01350897
Contributeur : Marie-Ange Di Carlo <>
Soumis le : mardi 2 août 2016 - 10:53:28
Dernière modification le : vendredi 5 août 2016 - 01:04:37
Document(s) archivé(s) le : mardi 8 novembre 2016 - 20:45:25

Fichier

Clar et al., HMG 2015.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Julie Clar, Elodie Mutel, Blandine Gri, Alison Creneguy, Anne Stefanutti, et al.. Hepatic lentiviral gene transfer prevents the long-term onset of hepatic tumours of glycogen storage disease type 1a in mice. Human Molecular Genetics, Oxford University Press (OUP), 2015, 24 (8), pp.2287-2296. <10.1093/hmg/ddu746>. <inserm-01350897>

Partager

Métriques

Consultations de
la notice

162

Téléchargements du document

67